Influenza and pneumococcal vaccine coverage in 584 patients taking biological therapy for chronic inflammatory joint: A retrospective study

2016 ◽  
Vol 83 (2) ◽  
pp. 155-159 ◽  
Author(s):  
Olivier Brocq ◽  
Emilie Acquacalda ◽  
Frédéric Berthier ◽  
Christine Albert ◽  
Gilles Bolla ◽  
...  
Author(s):  
M Sánchez-Regaña ◽  
J Sola-Ortigosa ◽  
M Alsina-Gibert ◽  
M Vidal-Fernández ◽  
P Umbert-Millet

2018 ◽  
Vol 21 ◽  
pp. S195
Author(s):  
P Santos-Moreno ◽  
D Buitrago-Garcia ◽  
L Villarreal ◽  
N Alvis-Zakzuk ◽  
M Carrasquilla ◽  
...  

The Lancet ◽  
2010 ◽  
Vol 375 (9709) ◽  
pp. 114-115 ◽  
Author(s):  
Norman Daniels ◽  
Atanacio Valencia-Mendoza ◽  
Adriane Gelpi ◽  
Mauricio Hernandez Avila ◽  
Stefano Bertozzi

2012 ◽  
Vol 3 ◽  
pp. S76 ◽  
Author(s):  
E. Topinkova ◽  
M. Chamradova Klaci Ramadhani ◽  
M. Novakova ◽  
F. Landi ◽  
J. Gindin ◽  
...  

Vaccine ◽  
2021 ◽  
Vol 39 (9) ◽  
pp. 1392-1401
Author(s):  
Yanling Liu ◽  
Wenhui Li ◽  
Qian Dong ◽  
Minqi Chen ◽  
Wenyu Li ◽  
...  

Vaccines ◽  
2021 ◽  
Vol 9 (3) ◽  
pp. 212
Author(s):  
Minyi Zhang ◽  
Hongbiao Chen ◽  
Fei Wu ◽  
Qiushuang Li ◽  
Qihui Lin ◽  
...  

Background: Elderly population is considered at high risk for pneumococcal diseases. The pneumococcal vaccine coverage presents extremely low among elderly people in China. However, the serious event of COVID-19 drives interest in the pneumococcal vaccine, prompting us investigating the willingness to accept the 23-valent pneumococcal polysaccharide vaccine (PPSV23) and influencing factors among people aged over 60 years during the COVID-19 pandemic. Methods: A cross-sectional study was employed using a self-administered questionnaire in Shenzhen City of China, elaborating the willingness toward PPSV23 in the elderly persons. Binomial logistic analyses were performed to estimate the influencing factors using odds ratios (ORs) and 95% confidence interval (CI). Results: Among 15,066 respondents, 91.5% presented a positive attitude toward PPSV23. Logistic analyses suggested the influencing factors included knowledge about pneumonia (adjusted OR [aOR] 1.391, 95%CI 1.214–1.593), perception of the seriousness of pneumonia (aOR 1.437, 95%CI 1.230–1.680) and preventing way for pneumonia (aOR 1.639, 95%CI 1.440–1.865), worried about getting pneumonia (aOR 2.751, 95%CI 2.444–3.096), understanding vaccine policy (aOR 1.774, 95%CI 1.514–2.079), and influenza vaccine (aOR 3.516 and 95%CI 2.261–5.468) and PPSV23 histories (aOR 3.199, 95%CI 1.492–6.860). Conclusions: The interest surge in pneumococcal vaccine coincided with the COVID-19 outbreak, foreshadowing higher demand for pneumococcal vaccine in the near future.


2020 ◽  
Author(s):  
Chrong-Reen Wang ◽  
Yi-Shan Tsai ◽  
Jiu-Yao Wang ◽  
Hung-Wen Tsai ◽  
Cheng-Han Lee

Abstract Background Cardiac insufficiency is a major cause of mortality in eosinophilic granulomatosis with polyangiitis (EGPA). Despite the dosages-related cardiotoxicity, cyclophosphamide is usually prescribed to induce disease remission in the presence of myocarditis with heart involvement. There is an imperative need of novel medications to efficiently control disease activity and spare the use of cyclophosphamide. Methods A retrospective study was carried out in hospitalized EGPA patients from January 1, 2008 to December 31, 2019, focusing on the use of biologics including benralizumab (BEN, anti-IL-5 receptor), mepolizumab (MEP, anti-IL-5), omalizumab (OMA, anti-IgE) and rituximab (RTX, anti-CD20). Results Sixteen admitted patients, 8 females aged 10 to 70 years (40.4 ± 15.5), had higher disease activities (Birmingham Vasculitis Activity Score 16 to 39, 26.8 ± 6.9), poorer prognostic factors (five-factor score 1 or 2, 1.4 ± 0.5) and elevated eosinophil counts (2,314 to 26,781/µL, 11,108 ± 7,060). BEN, MEP, OMA and RTX were prescribed in one, 2, one and 6 patients, respectively. Ten patients (63%) had myocarditis with impaired left ventricle ejection fraction and cardiac arrhythmia, and 7 received biological therapy without a combined use of cyclophosphamide. One patient obtained MEP with a 100 mg quadri-weekly × 13 regimen at induction for disease relapse. Six patients acquired RTX with a 375 mg/m2 weekly × 4 regimen at induction for refractory activity or relapsing disease, or plus a yearly maintenance schedule in 5. All patients received serial cardiac magnetic resonance imaging, transthoracic echocardiography and 24-hour Holter monitor to evaluate the therapeutic responses in heart involvement. After biological therapy, there were improved cardiac dysfunction, lower eosinophil counts and clinical remission (4 complete, 3 partial) with a relapse-free follow-up (13 to 61 months, 39.1 ± 16.0) after induction. Conclusions In this single-center retrospective study, we observed improved cardiac dysfunction and disease activity after biological therapy in EGPA patients with myocarditis.


2021 ◽  
Vol 9 (11) ◽  
pp. 2342
Author(s):  
Nobuhiro Asai ◽  
Hiroshige Mikamo

Pneumococcal disease is one of the most common and severe vaccine-preventable diseases (VPDs). Despite the advances in antimicrobial treatment, pneumococcal disease still remains a global burden and exhibits a high mortality rate among people of all ages worldwide. The immunization program of the pneumococcal conjugate vaccine (PCV) in children has decreased pneumococcal disease incidence in several countries. However, there are several problems regarding the pneumococcal vaccine, such as indications for immunocompetent persons with underlying medical conditions with a risk of pneumococcal disease, the balance of utility and cost, i.e., cost-effectiveness, vaccine coverage rate, serotype replacement, and adverse events. Especially for individuals aged 19–64 at risk of pneumococcal disease, physicians and vaccine providers should make a rational decision whether the patients should be vaccinated or not, since there is insufficient evidence supporting it. We describe this review regarding topics and problems regarding pneumococcal vaccination from the clinician’s point of view.


2020 ◽  
Vol 8 (3) ◽  
Author(s):  
Mulualem A. Endalew ◽  
Fekadu S. Wakene

Ethiopia has huge numbers of livestock hampered with high prevalence of infectious disease due to poor disease prevention and control. A five-year retrospective study was conducted to collect data on commonly diagnosed bacterial and viral disease and associated vaccine available at district government veterinary clinic in 2019. The commonly encountered bacterial and viral cattle diseases recorded in the case record book were LSD, CBPP Black leg, Anthrax, Bovine pasteurellosis, and Mastitis. Sheep and goat pox disease, Ovine Pasteurellosis, PPR, CCPP, and anthrax were the common diseases of sheep and goat in the study district. Regarding diseases of poultry, New castle, Infectious Bursal Diseases (Gumboro), Infectious coriza, chicken pox, Coccidiosis, Fowl Typhoid, Fowl Cholera, and Marex are the major once. The commonly available vaccines in the study district were LSD, Black leg, Anthrax, Bovine pasteurellosis, Ovine pasteurellosis, Sheep and Goat Pox, PPR, and vaccine for chicken disease like New castle disease vaccine, Gumboro, Fowl Pox, Fowl typhoid and Fowl cholera were used. Vaccination coverage for Lumpy Skin Disease, Sheep and Goat pox and Newcastle viral diseases were good compared with other diseases. The majority 36% of the population of cattle were vaccinated for LSD in 2019 and the lowest 16% in 2015.The lower portion of shoat 8% and half of the population 50% were vaccinated in 2017 and 2019 respectively. Maximum proportion of Newcastle and Gumboro vaccination coverage were 53% and 42%. The vaccination trends for most of the vaccines were fluctuating from year to year whereas the vaccination trend for LSD was increasing from year to year.


Sign in / Sign up

Export Citation Format

Share Document